{"nctId":"NCT00855920","briefTitle":"Study Utilizing Rilonacept in Gout Exacerbations","startDateStruct":{"date":"2009-03"},"conditions":["Acute Gout Flare"],"count":225,"armGroups":[{"label":"Placebo (for Rilonacept) and Indomethacin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Indomethacin","Other: Placebo (for Rilonacept)"]},{"label":"Rilonacept and Indomethacin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rilonacept","Drug: Indomethacin"]},{"label":"Rilonacept and Placebo (for Indomethacin)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rilonacept","Other: Placebo (for Indomethacin)"]}],"interventions":[{"name":"Rilonacept","otherNames":[]},{"name":"Indomethacin","otherNames":[]},{"name":"Placebo (for Indomethacin)","otherNames":[]},{"name":"Placebo (for Rilonacept)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female 18 - 70 years of age\n2. Previously met the preliminary criteria of ARA for the classification of the acute arthritis of primary gout\n3. Presenting with an acute attack (flare) of gout within 48 hours of pain onset and pain of at least moderate severity\n4. Must have at least 1 on the 0-3 scale for the swelling and the tenderness assessments of the gouty index joint\n5. Current presentation of acute gout flare in 3 joints or less\n\nExclusion Criteria:\n\n1. Treatment with any non-steroidal anti-inflammatory drug (NSAIDs) or opiates within 48 hours prior to baseline assessments. Treatment with long-acting NSAIDs within 1 month prior to baseline visit. Treatment with naproxen, meloxicam, nabumetone, celecoxib and indomethacin SR within 5 days prior to baseline visit.\n2. Treatment with oral analgesics within 6 hours before baseline assessments. Treatment with topical analgesics within 12 hours before baseline assessments\n3. History of NSAID intolerance\n4. Participants with history of chronic, gouty arthritis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 Hours","description":"Participants were asked to complete a daily diary entry and assessed their pain in the past 24 hours using 5-point Likert Scale of 0 (None) to 4 (extreme pain), where; 0= none, 1= mild pain, 2= moderate pain, 3= severe pain, or 4= extreme pain. Change in PAP-LS in the index joint from baseline (Day 1) to the averaged PAP-LS values at 24, 48 and 72 hours was reported in this outcome measure (averaged PAP value= \\[PAP at 24 hours + PAP at 48 hours + PAP at 72 hours\\]/3).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.40","spread":"0.956"},{"groupId":"OG001","value":"-1.55","spread":"0.919"},{"groupId":"OG002","value":"-0.69","spread":"0.970"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint at 72 Hours","description":"Participants were asked to complete a daily diary entry and assessed their pain in the past 24 hours using 5-point Likert Scale of 0 (None) to 4 (extreme pain), where; 0= none, 1= mild pain, 2= moderate pain, 3= severe pain, or 4= extreme pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.41","spread":"0.865"},{"groupId":"OG001","value":"-1.57","spread":"1.104"},{"groupId":"OG002","value":"-1.29","spread":"0.976"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint at 48 Hours","description":"Participants were asked to complete a daily diary entry and assessed their pain in the past 24 hours using 5-point Likert Scale of 0 (None) to 4 (extreme pain), where; 0= none, 1= mild pain, 2= moderate pain, 3= severe pain, or 4= extreme pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.36","spread":"0.883"},{"groupId":"OG001","value":"-1.54","spread":"0.959"},{"groupId":"OG002","value":"-1.08","spread":"1.057"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint at 24 Hours","description":"Participants were asked to complete a daily diary entry and assessed their pain in the past 24 hours using 5-point Likert Scale of 0 (None) to 4 (extreme pain), where; 0= none, 1= mild pain, 2= moderate pain, 3= severe pain, or 4= extreme pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.16","spread":"1.021"},{"groupId":"OG001","value":"-1.44","spread":"0.895"},{"groupId":"OG002","value":"-0.55","spread":"0.845"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":77},"commonTop":["Headache","Dizziness"]}}}